- Home
- OSUR vs URGN Comparison
OSUR vs URGN Comparison
Compare OSUR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- URGN
- Stock Information
- Founded
- OSUR 2000
- URGN 2004
- Country
- OSUR United States
- URGN United States
- Employees
- OSUR N/A
- URGN N/A
- Industry
- OSUR Medical/Dental Instruments
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- URGN Health Care
- Exchange
- OSUR Nasdaq
- URGN Nasdaq
- Market Cap
- OSUR 223.0M
- URGN 181.2M
- IPO Year
- OSUR 1986
- URGN 2017
- Fundamental
- Price
- OSUR $3.00
- URGN $14.82
- Analyst Decision
- OSUR Hold
- URGN Strong Buy
- Analyst Count
- OSUR 1
- URGN 9
- Target Price
- OSUR $3.00
- URGN $26.81
- AVG Volume (30 Days)
- OSUR 804.6K
- URGN 5.9M
- Earning Date
- OSUR 08-05-2025
- URGN 08-12-2025
- Dividend Yield
- OSUR N/A
- URGN N/A
- EPS Growth
- OSUR N/A
- URGN N/A
- EPS
- OSUR N/A
- URGN N/A
- Revenue
- OSUR $161,626,000.00
- URGN $91,871,000.00
- Revenue This Year
- OSUR N/A
- URGN $36.65
- Revenue Next Year
- OSUR $6.20
- URGN $88.35
- P/E Ratio
- OSUR N/A
- URGN N/A
- Revenue Growth
- OSUR N/A
- URGN 8.98
- 52 Week Low
- OSUR $2.36
- URGN $3.42
- 52 Week High
- OSUR $4.92
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- OSUR 54.60
- URGN 73.80
- Support Level
- OSUR $2.78
- URGN $6.92
- Resistance Level
- OSUR $3.03
- URGN $15.22
- Average True Range (ATR)
- OSUR 0.13
- URGN 1.57
- MACD
- OSUR 0.01
- URGN 1.17
- Stochastic Oscillator
- OSUR 58.93
- URGN 96.49
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.